Evaluation of pomalidomide with dexamethasone (low dose) in patients with Multiple Myeloma (MM)whose disease did not respond to the previous treatment or, has come back after the previous treatment. : A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

Medienart:

Klinische Studie

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

WHO International Clinical Trials Registry Platform - (2023) vom: 21. Juni Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: Refractory multiple myeloma (MM) or relapsed and refractory MM. MedDRA version: 18.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
Phase: Phase 3
Recruitment Status: Not yet recruiting
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 29-10-2012, Last updated: 2023-06-29

ICTRP ID:

EUCTR2012-001888-78-BE
CC-4047-MM-010
NCT01712789
2012-001888-78-ES

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG00431333X